| Autor: |
Kalafat, E., O'Brien, P., Heath, P. T., Le Doare, K., Dadelszen, P., Magee, L., Ladhani, S., Khalil, A., von Dadelszen, P |
| Předmět: |
|
| Zdroj: |
Ultrasound in Obstetrics & Gynecology; May2021, Vol. 57 Issue 5, p681-686, 6p |
| Abstrakt: |
Historically, pregnant women have been excluded from the majority of drug and vaccine trials, a practice that has been criticized widely by the scientific community1-3. The principles of this vaccination technology should also apply to COVID-19 vaccines and provides generic reassurance around the use of mRNA vaccines in pregnancy. Available SARS-CoV-2 vaccines and their safety profiles Four different types of COVID-19 vaccine are currently available (Table 3): mRNA, viral vector, inactivated virus and recombinant antigen. As with the mRNA vaccines, there are limited data on the safety of adenovirus vector-based vaccines in pregnancy, though adenovirus vector-based Zika virus vaccines have been tested in pregnant mice without safety concerns35. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text